VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

C. psittaci DNA vaccine pcDNA1/MOMP
Vaccine Information
  • Vaccine Ontology ID: VO_0011426
  • Type: DNA vaccine
  • Status: Research
  • Antigen: C. psittaci ompA
  • ompA gene engineering:
    • Type: DNA vaccine construction
    • Description: To enhance the expression of MOMP in turkey cells, the coding sequence of the ompA gene was adapted and optimised to the codon usage in birds (GenScript Corporation, New Jersey, USA) in order to increase the codon adaptation index (CAI). The CAI was calculated (http://www.evolvingcode.net/codon/cai/cai.php) based on the most frequent codon usage in chickens and turkeys. EGFP was cloned downstream from the codon optimised ompAopt into the EcoRV restriction site of pcDNA1, resulting in the final construct: pcDNA1/MOMPopt–EGFP. Plasmid DNA was propagated in Escherichia coli MC1061/P3, purified using the EndoFree® Plasmid Giga kit (Qiagen, Venlo, The Netherlands) and dissolved in 20 mM Hepes buffer (pH 7.4). Following purification, a PCR reaction on the plasmid was performed with vector associated SP6 and T7 primers to amplify the fusion construct cloned into the multicloning site of pcDNA1(Verminnen et al., 2010).
    • Detailed Gene Information: Click Here.
  • Vector: pcDNA1
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Turkey Response

  • Host Strain: SPF
  • Vaccination Protocol: Three groups received a primary DNA inoculation at 1 day of age and one booster inoculation 3 weeks later. Groups 1 and 2 were twice immunised intramuscularly with respectively naked plasmid DNA or brPEI-pcDNA/MOMPopt, while group 3 was vaccinated at both time points through nebulisation of brPEI-pcDNA/MOMPopt. The control group (4) was left unvaccinated (Verminnen et al., 2010).
  • Challenge Protocol: Turkeys were challenged by aerosol infection at the age of 5.5 weeks using the Cirrus™ nebulizer. The challenge infection consisted of 108 TCID50 of Cp. psittaci strain 92/1293 (avian genotype D strain). All turkeys were euthanized at 25 days post-challenge (PC) (Verminnen et al., 2010).
  • Efficacy: The ompA codon was adapted to the codon usage in birds, resulting in pcDNA1/MOMP(opt). Researchers examined the capacity of nebulised or intramuscularly (IM) administered brPEI-pcDNA1/MOMP(opt) to induce a significant protective immune response in SPF turkeys experimentally infected with 108 TCID(50) of a virulent Cp. psittaci strain. Vaccinated groups were significantly protected against Cp. psittaci challenge (Verminnen et al., 2010).
References
Verminnen et al., 2010: Verminnen K, Beeckman DS, Sanders NN, De Smedt S, Vanrompay DC. Vaccination of turkeys against Chlamydophila psittaci through optimised DNA formulation and administration. Vaccine. 2010; 28(18); 3095-3105. [PubMed: 20199760].